Of these, 15% (n = 386 tumours from 372 patients) were deficient in MSH2, MSH6 or PMS2 (but MLH1-proficient), so were eligible for germline testing; 121 of these patients (33%) received a germline test. Here, MSH2 is linked to neoplasm.